The novel new vaccine, which involves injecting weakened malarial-inducing parasites into patients in order to elicit a degree of immunity, has been having successful results. The U.S. biotech company, Sanaria, hopes for continued success in order to alleviate the impact of the widespread disease.
NOT FOR REPRINT
© Arc, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to TMSalesOperations@arc-network.com. For more information visit Asset & Logo Licensing.